Results 41 to 50 of about 425,993 (391)
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 2021 Background: Approximately 5-60% of hemodialysis patients have comorbid of hepatitis C virus (HCV) infection. The survival rate of hemodialysis patients HCV is lower than those without HCV due to the risk of liver fibrosis and cardiovascular disease.
Bayu Laksono +4 more
doaj +1 more source
The prevalence of hepatitis C virus among people of South Asian origin in Glasgow: results from a community based survey and laboratory surveillance [PDF]
, 2013 Background South Asians often present late with HCV or HBV related liver disease which could have been avoided with early diagnosis and subsequent treatment; however the prevalence of HCV/HBV among South Asians in Glasgow is not known.
Ahmed, S. +14 more
core +2 more sources
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
New England Journal of Medicine, 2014 BACKGROUND Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need.
N. Afdhal +24 more
semanticscholar +1 more source
Health disparities in chronic liver disease
Hepatology, EarlyView., 2022 Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian +3 more
wiley +1 more source
Farmeconomia: Health Economics and Therapeutic Pathways, 2008 The current standard of care for the treatment of chronic hepatitis C virus (HCV) infection is combination therapy with Peg-interferon (IFN) alpha-2a or alpha-2b type plus ribavirin (RBV).
Luisa Cavalletto +5 more
doaj +1 more source
Journal of Pure and Applied Microbiology, 2023 The invasion and spread of cancer cells are two of the most notable characteristics of malignant tumors. Recent studies suggest that the epithelial-mesenchymal transition (EMT) has been linked to this significant occurrence.
May K. Ismael +3 more
doaj +1 more source
Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR [PDF]
, 2019 The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who ...
Berenguer, Juan +14 more
core +4 more sources
Gastroenterology, 2019 BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is an important risk factor for hepatocellular carcinoma (HCC). Despite effective antiviral therapies, the risk for HCC is decreased but not eliminated after a sustained virologic response (SVR)
Nourdine Hamdane +34 more
semanticscholar +1 more source
Viruses, 2009 One year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided.
P. Lampertico +3 more
openaire +4 more sources
Identification of novel neutralizing determinants for protection against HCV
Hepatology, EarlyView., 2022 Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua +12 more
wiley +1 more source